IP Library Granted Patent US 10,828,325
Granted Patent B2
US 10,828,325 · App. 16/211,705 · Granted Nov 10, 2020

Hypochlorite compositions for the treatment of traumatic brain injury

Inventor: Kurt Richards (Herriman, UT)
Assignee: REOXCYN, LLC
A61K33/20A61K9/08A61K47/02A61K47/24A61P25/00A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,828,325
App. No.
16/211,705
Granted
Nov 10, 2020
Kind
B2
Abstract

Described herein are compositions that include hypochlorite and methods of alleviating, ameliorating, palliating, reducing, or treating a traumatic brain injury or neurological disorder, such as a concussion, with such composition. The composition may further include a salt, a buffer, a rheology agent, or a silicone polymer or blend thereof. The salt may include halite, table salt, common salt, curing salt, flake salt, Epsom salt, sea salt, Alaea salt (or Hawaiian sea salt), Alpenbergkern salt, Anglesey Sea salt, Dead Sea salt, Himalayan sea salt, Kalahari salt, Maras salt, Murray River salt flakes, Namibian salt pearls, Persian blue fine salt, Polish mine salt, primordial sea salts, Sal de Tavira, Sale Marino di Trapani, Sel de Guérande, South African Sea salt, Utah salt, black lava salt, brine, rock salt, red rock salt, or kosher salt, or combinations thereof.

Claims (20)

1. A method of treating a traumatic brain injury (TBI) in a subject, comprising:

administering to the subject a composition comprising hypochlorite, a salt present in an amount of about 0.01% to about 0.1% w/v, a buffer present in an amount of about 0.5% to about 5% w/v, wherein the buffer comprises sodium phosphate monobasic, a rheology agent present in an amount of about 0.5% to about 10% w/v, wherein the rheology agent comprises sodium magnesium silicate, and a silicone polymer or blend thereof present in an amount of about 0.5% to about 10% w/v, wherein the silicone polymer or blend thereof comprises dimethicone,

wherein the composition is administered by nasal, oral, parenteral, pulmonary, rectal, sublingual, or vaginal administration.

2. The method of claim 1 , wherein the salt comprises halite, table salt, common salt, curing salt, flake salt, Epsom salt, sea salt, Alaea salt (or Hawaiian sea salt), Alpenbergkern salt, Anglesey Sea salt, Dead Sea salt, Himalayan sea salt, Kalahari salt, Maras salt, Namibian salt pearls, Persian blue fine salt, Polish mine salt, primordial sea salts, Sal de Tavira, Sale Marino di Trapani, Sel de Guérande, South African Sea salt, Utah salt, black lava salt, brine, rock salt, red rock salt, or kosher salt, or combinations thereof.

3. The method of claim 1 , wherein the composition is formulated as a pharmaceutically acceptable dosage form.

4. The method of claim 1 , wherein the TBI is a concussion.

5. The method of claim 1 , wherein the composition is formulated as an aerosol, a balm, a bead, a caplet, a capsule, a cream, a dragee, a drop, an emollient, a foam, a gel, a granule, a gummy, an inhalable, an injectable, a liquid, a lotion, a lozenge, a meltable solid, a mist, an ointment, a paste, a patch, a pellet, a pill, a powder, a slurry, a soft gel, a solution, a sponge, a spray, a spritz, a strip, a suppository, a suspension, a syrup, a tablet, a tape, or a vapor.

6. The method of claim 1 , wherein the composition is administered to the subject at least twice daily.

7. The method of claim 1 , wherein administration of the composition reduces symptoms of a TBI.

8. The method of claim 1 , wherein the composition is administered by nasal administration.

9. The method of claim 1 , wherein the composition is administered by oral administration.

10. The method of claim 1 , wherein the composition is administered by parenteral administration.

11. The method of claim 1 , wherein the composition is administered by pulmonary administration.

12. The method of claim 1 , wherein the composition is administered by rectal administration.

13. The method of claim 1 , wherein the composition is administered by sublingual administration.

14. The method of claim 1 , wherein the composition is administered by vaginal administration.

15. The method of claim 1 , wherein the composition is administered in an amount of about 0.1 ounces to about 12 ounces.

16. The method of claim 1 , wherein the TBI is a chronic brain injury.

17. The method of claim 1 , wherein the hypochlorite is present in an amount of about 10 ppm to about 300 ppm.

18. The method of claim 1 , wherein the hypochlorite is present in an amount of about 75 ppm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: RICHARDS, KURT
To: REOXCYN INNOVATION GROUP, LLC
Reel/Frame 053873/0758 →
CHANGE OF NAME Recorded Sep 24, 2020
From: REOXCYN INNOVATION GROUP, LLC
To: REOXCYN, LLC
Reel/Frame 053879/0201 →
Continuity (2)
Provisional Application 62609810 · Dec 22, 2017
Related Publication 20190192557A1 · Jun 27, 2019